Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s stock price was up 1% during trading on Thursday . The company traded as high as $6.52 and last traded at $6.30. 1,945,327 shares were traded during trading, an increase of 476% from the average session volume of 337,931 shares. The stock had previously closed at $6.24.
Silverback Therapeutics Price Performance
The firm has a market cap of $198.50 million, a price-to-earnings ratio of -2.27 and a beta of 0.60. The stock has a 50 day moving average of $7.33 and a 200 day moving average of $8.19.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
See Also
- Five stocks we like better than Silverback Therapeutics
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
- Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch
- MarketBeat Week in Review – 08/17 – 08/21
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
